Reviewing RYTHM (RYM) & Its Competitors

RYTHM (NASDAQ:RYM) is one of 906 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare RYTHM to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.

Earnings and Valuation

This table compares RYTHM and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$17.28 million	-$33.26 million	-2.15
RYTHM Competitors	$3.46 billion	$3.10 billion	549.80

RYTHM’s peers have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares RYTHM and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,303.77%	-221.69%	-17.78%

Volatility and Risk

RYTHM has a beta of 9.47, suggesting that its share price is 847% more volatile than the S&P 500. Comparatively, RYTHM’s peers have a beta of -3.18, suggesting that their average share price is 418% less volatile than the S&P 500.

Insider & Institutional Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for RYTHM and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7718	13662	25546	994	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.65%. Given RYTHM’s peers stronger consensus rating and higher probable upside, analysts clearly believe RYTHM has less favorable growth aspects than its peers.

Summary

RYTHM peers beat RYTHM on 9 of the 13 factors compared.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.